Literature DB >> 12702875

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Rakez Kayed1, Elizabeth Head, Jennifer L Thompson, Theresa M McIntire, Saskia C Milton, Carl W Cotman, Charles G Glabe.   

Abstract

Soluble oligomers are common to most amyloids and may represent the primary toxic species of amyloids, like the Abeta peptide in Alzheimer's disease (AD). Here we show that all of the soluble oligomers tested display a common conformation-dependent structure that is unique to soluble oligomers regardless of sequence. The in vitro toxicity of soluble oligomers is inhibited by oligomer-specific antibody. Soluble oligomers have a unique distribution in human AD brain that is distinct from fibrillar amyloid. These results indicate that different types of soluble amyloid oligomers have a common structure and suggest they share a common mechanism of toxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702875     DOI: 10.1126/science.1079469

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  1344 in total

1.  Dynamic imaging by fluorescence correlation spectroscopy identifies diverse populations of polyglutamine oligomers formed in vivo.

Authors:  Monica Beam; M Catarina Silva; Richard I Morimoto
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

Review 2.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

3.  An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies.

Authors:  Deborah A Ryan; Wade C Narrow; Howard J Federoff; William J Bowers
Journal:  J Neurosci Methods       Date:  2010-05-07       Impact factor: 2.390

4.  Stable and metastable states of human amylin in solution.

Authors:  Allam S Reddy; Lu Wang; Sadanand Singh; Yun L Ling; Lauren Buchanan; Martin T Zanni; James L Skinner; Juan J de Pablo
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

5.  Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Authors:  Judith Eschbach; Björn von Einem; Kathrin Müller; Hanna Bayer; Annika Scheffold; Bradley E Morrison; K Lenhard Rudolph; Dietmar R Thal; Anke Witting; Patrick Weydt; Markus Otto; Michael Fauler; Birgit Liss; Pamela J McLean; Albert R La Spada; Albert C Ludolph; Jochen H Weishaupt; Karin M Danzer
Journal:  Ann Neurol       Date:  2014-12-19       Impact factor: 10.422

6.  Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.

Authors:  Asad Jan; Dean M Hartley; Hilal A Lashuel
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

7.  Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models.

Authors:  Qiu-Lan Ma; Marni E Harris-White; Oliver J Ubeda; Mychica Simmons; Walter Beech; Giselle P Lim; Bruce Teter; Sally A Frautschy; Greg M Cole
Journal:  J Neurochem       Date:  2007-08-30       Impact factor: 5.372

Review 8.  Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity.

Authors:  Roberto Cappai; Kevin J Barnham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

9.  Phenotype of cardiomyopathy in cardiac-specific heat shock protein B8 K141N transgenic mouse.

Authors:  Atsushi Sanbe; Tetsuro Marunouchi; Tsutomu Abe; Yu Tezuka; Mizuki Okada; Sayuri Aoki; Hideki Tsumura; Junji Yamauchi; Kouichi Tanonaka; Hideo Nishigori; Akito Tanoue
Journal:  J Biol Chem       Date:  2013-02-06       Impact factor: 5.157

10.  Sumo E2 enzyme UBC9 is required for efficient protein quality control in cardiomyocytes.

Authors:  Manish K Gupta; James Gulick; Ruijie Liu; Xuejun Wang; Jeffery D Molkentin; Jeffrey Robbins
Journal:  Circ Res       Date:  2014-08-05       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.